Loading
Lung cancer doctor who led PHAROS, the trial that brought the encorafenib and binimetinib pair to BRAF V600E-mutant lung cancer.
Gregory Riely is a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center. He was first author of the 2023 Journal of Clinical Oncology report of PHAROS, the phase 2 trial of encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer that supported the combination's approval, and has long worked on KRAS-mutant lung cancer and the clinical use of tumour genotyping.
| Title | Journal | Year |
|---|---|---|
| PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer | Journal of Clinical Oncology | 2023 |
Encorafenib-binimetinib is approved for BRAF V600E lung cancer and offers a second targeted option, particularly for patients troubled by fever on dabrafenib-trametinib.
It turned a frequently reported variant into an interpretable one: the class decides whether the stain will be negative, how poor the prognosis is, and whether immunotherapy is more rather than less likely to help.
It separated the prognostic co-mutation, KEAP1, from the predictive one, STK11, in a disease where the two are often quoted together, and it is the reason KEAP1 status is worth reading off a report even though no treatment depends on it.
It is the honest accounting of precision oncology in the disease where it works best: broad sequencing changes treatment for about one patient in three, and the bottleneck is evidence rather than detection.
It is the reference frequency table for resistance to first-generation EGFR inhibitors, and it made rebiopsy at progression standard rather than exceptional, because the mechanism decides the next treatment and cannot be guessed.
Shares Memorial Sloan Kettering Cancer Center, Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.